We transplanted 4.1 ؋ 10 7 unrelated umbilical cord blood cells into a 27-year-old patient suffering from transformed acute myelocytic leukemia. The thawing method was the same as described by Rubinstein et al (Proc Natl Acad Sci USA 1995; 92: 10119-10122). ANC reached over 500 ؋ 10 9 /l on day 19, and the patient was free from RBC and platelet transfusion on days 26 and 38, respectively. Cytogenetic and molecular analysis after transplant revealed complete chimerism. The CD3 +
/l at 5 weeks after transplantation. The CD3

+
CD8
+ count became greater than 500 ؋ 10 9 /l at 7 weeks and thereafter progressively increased in spite of administration of CYA. This immunological reconstitution pattern after umbilical cord blood transplantation was different from that after bone marrow transplantation, and resistance of CD3 + CD8 + lymphocytes to CYA was the distinguishing characteristic. The rapid hematological recovery and immunological reconstitution may be attributed to the high dose of transfused nucleated cells and umbilical cord blood transplantation may become a promising method for treatment for such cases. Keywords: cord blood transplantation; engraftment; reconstitution Umbilical cord blood is an alternative hematopoietic stem cell source to allogeneic bone marrow. [1] [2] [3] [4] [5] [6] [7] Indications for umbilical cord blood transplantation are mostly limited to children because of the small number of stem cells available. Recently, umbilical cord blood has been transplanted into adult patients in many centers. [2] [3] [4] [5] [6] [7] Viral and fungal infections are serious problems of umbilical cord blood transplantation because the engraftment is delayed compared to conventional allogeneic bone marrow transplanCorrespondence: Dr H Nagayama, Department of Cell Processing, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minatoku, Tokyo 108-8639, Japan Received 23 December 1998; accepted 7 March 1999 tation. [2] [3] [4] [5] [6] [7] The frequency of infectious complications is closely related to the number of donor-derived T cells and their immunological reconstitution after transplantation. Therefore, it is important to explore the T cell number and reconstitution pattern in the case of umbilical cord blood transplantation. Although there are some reports examining T cells after umbilical cord blood transplantation, 2,3 the profile of T cell recovery during the course of treatment has not been fully elucidated. In the present study we examined CD3 + CD4 + and CD3 + CD8 + cells in the early phase of umbilical cord blood transplantation in an adult female patient.
Case report
A 27-year-old female patient suffering from secondary acute myelocytic leukemia transformed from myelodysplastic syndrome was referred to our hospital in August 1998. Her condition was diagnosed as refractory anemia with excess blasts (RAEB) in March 1990, and was treated with immunosuppressive therapy using prednisolone and metenolone acetate for 8 years. She had also been transfused with over 80 units of concentrated red blood cells and 500 units of platelet-rich plasma.
In May 1998, she experienced fever and general malaise, and visited Nippon Medical School Hospital. After bone marrow examination, she was diagnosed as having acute myelocytic transformation from RAEB. After she entered the hospital, she suffered from frequent infections including subacute bacterial pericarditis and phlegmon of the right lower limb. We intended to treat her with stem cell transplantation because she was unlikely to attain complete remission with conventional chemotherapy, and because we wanted to avoid undesirable organ damage before transplantation. However, there was no suitable candidate among related and unrelated bone marrow donors. We searched for a matched stem cell source at the Tokyo Cord Blood Bank, where umbilical cord blood stem cell sources are cryopreserved according to Rubinstein et al's method. 1 Finally we found a two-antigen mismatched unrelated umbilical cord blood. Characteristics of this umbilical cord blood are shown in Table 1 . This lot was serologically negative for HBV, HCV, HIV1/2, ATLL and syphilis. Both the maternal and the patient's blood were positive for CMV-IgG but negative for CMV-IgM (examined by EIA). The institutional review board consented to this transplantation. After signed informed consent was obtained, we transplanted the umbilical cord blood. Before transplant, the patient's bone marrow was 82.4% occupied by blast cells, which possessed chromosomal abnormality, 48,XX,+21,+mar (19/20 cells). The conditioning regimen consisted of threefractionated 12 Gy total body irradiation from day Ϫ9 to day Ϫ7, rG-CSF (5 g/kg/day continuous i.v. infusion on days Ϫ5 and Ϫ4), cytarabine (3 g/m 2 twice daily i.v. on days Ϫ5 and Ϫ4 (total of four doses)), and cyclophosphamide (60 mg/kg once daily i.v. on days Ϫ3 and Ϫ2 (total dose 120 mg/kg)). 8, 9 After conditioning, a total of 4.1 ϫ 10 7 nucleated cells were infused (Table 1) , the thawing method being the same as described by Rubinstein et al. 1 GVHD prophylaxis consisted of cyclosporine (3 mg/kg once daily i.v. infusion over 10 h) and short-term MTX (15 mg/m 2 i.v. on day 1, 10 mg/m 2 on days 3 and 6). rG-CSF (5 g/kg/day) was also intravenously administered with the aim of obtaining a rapid recovery of granulocytes from day 1. On day 11, pyrexia over 38°C occurred, and multi-drug-resistant Pseudomonas aeruginosa was detected from the culture of her throat exudate. We altered the antibiotics from vancomycin and ceftazidim to meropenem, cefozoplan and tobramycin. On day 19 the neutrophil count reached over 500 ϫ 10 9 /l. We therefore considered that the umbilical cord blood had engrafted successfully. The reticulocyte count rose above 1% of the total red blood cells on day 25, and the platelet count reached over 50 000 ϫ 10 9 /l on day 50. On day 29, all of her analyzed bone marrow mononuclear cells (20/20 cells) possessed a male karyotype (46,XY) of donor origin, and hyperdiploid cells having 48,XX,+21,+mar disappeared. Molecular analysis of her peripheral blood mononuclear cells using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) technique showed donor-type HLA-DRB1 0101 and 0802 bit pattern. A fluorescence in situ hybridization technique using a Y chromosome-specific probe (day 55) proved that all analyzed cells (511 cells) had donorderived Y signals and no recipient-derived XX signals, indicating that complete chimerism was attained.
During the course, a maculopapular rash and diarrhea developed. Biopsies of cutaneous (day 42) and gastric mucosa (day 50) revealed the existence of acute GVHD. The overall grade was II. The number of T cells after transplantation in this patient is shown in Figure 1 (diamonds with solid lines) . Until 8 weeks after transplantation, CYA (4.8 mg/kg p.o. daily in divided dose) was administered. The number of CD3 + CD4 + cells ranged from 100 to 250 ϫ 10 9 /l. In contrast, the number of CD3 + CD8 + cells was less than 100 ϫ 10 9 /l until 6 weeks after transplantation. Thereafter the number began to progressively increase in spite of the administration of CYA (Figure 1) . Because the grade of GVHD was not severe, and because recurrence of the disease had to be prevented, CYA administration was discontinued at the end of 
CD4
+ and CD3 + CD8 + cells were counted using a 4T8 assay kit (Biometric Imaging, Mountain View, CA, USA). CYA was administered to the 27-year-old female patient according to the protocol indicated at the bottom. FK506 (0.03 mg/kg) was administered to the control patient throughout the treatment course. /l). On day 58 she was discharged without major complications, and complete remission has persisted for over 180 days after transplantation.
Discussion
In this report we presented an adult female patient with acute myelocytic leukemia who was successfully treated with unrelated umbilical cord blood transplantation. There are few reports examining CD4
+ and CD8 + cells after umbilical cord blood transplantation for hematological malignancies. However, the successive alterations of these cells during the treatment in adult patients have not been reported. Kurtzberg et al 2 reported the absolute lymphocyte counts, CD4/8 ratio, and in vitro mitogenic responses in 13 paediatric patients, and 10 cases were analyzed before day 100 after transplantation. Three patients showed a high number of CD8 + cells, greater than 1000 × 10 9 /l, in spite of the administration of CYA. McDouall et al 10 have reported that CD4 + and CD8 + cells from cord blood are highly sensitive to CYA. CYA inhibits the proliferation of CD4 + and CD8 + cells from cord blood much more effectively than those from adult subjects. This result is different from the data of Kurtzberg et al and ours, suggesting that umbilical cord blood-derived T cells transplanted in vivo obtain some ability to resist the action of CYA. Because the proliferation of CD3 + CD4 + and CD4 + CD8 + cells from adult bone marrow was inhibited by immunosuppressants (Figure 1) , the resistance to CYA is not ascribed to the transplantation itself but to the peculiar characteristics of umbilical cord blood-derived T cells.
Kurtzberg et al reported the rapid myeloid engraftment of umbilical cord blood employing a new thawing technique, 1,2 as was the case of our patient. The rapid recovery of CD3 +
CD4
+ and CD3 + CD8 + cells may be ascribed to the high dose of transfused nucleated cells. The presence of sufficient numbers of CD3 + CD4 + and CD3 + CD8 + cells is beneficial for the prevention of infections and recurrence of the original disease and, thus, umbilical cord blood transplantation may be a promising method to treat hematological malignancies in adult patients.
